Komori
DyDo GROUP HOLDINGS (2590) · PolicyFirst stated

Separate disclosure of the orphan drug business as a reportable segment

First written in FY2023-Q1. . Latest entry: FY2023-Q1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Establishment of an Independent Reportable Segment for the Orphan Drug BusinessA theme 1 companies write about · 0 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023-Q1First statedAnnual report

    「当第１四半期連結累計期間より、これまで「その他」に含めておりました「希少疾病用医薬品事業」の金額的重要性が増したため、報告セグメントとして記載する方法に変更しております。」

    希少疾病用医薬品事業の金額的重要性が増したことから、従来の「その他」から独立した報告セグメントとして表示する方法へ変更した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for DyDo GROUP HOLDINGS yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.